Balance Sheet As at l August 2025 Notes 2025 CurrentAssets Cash at bank and In hand 402.750.32 Totsl Current Assets 402,750.32 Other debtors Prepayments 92.11 Current Llablutles Total Assets less Current Uabllltles 402,842.43 NetAsseis ReseNes Unrestricted ReseNes Restricted ReseNes 2,924.85 402.054.48 Total ReseTh*s Approved bythe Trustees on 28 May 2026 and slgned on thelr behalf by: Trustee 4￿¥ ststement of FlnanclalA¢llvltles-Sldefxhub Income and Expenfllture Forthe perlod ended IAugust 2025 Unrestrt¢ledfunds Re5trlcted funds Total Funds to the nearest£ to nearest £ to tho n•arest£ Al Re¢elpls UK Donations in GBP UK donations in Kind Non-UKdonations in GBP Bank Interest 2380 400000 402380 291 291 31.48 31.48 Non-UK donations in Euros IGBP equivalentl 47.84 47.84 Sub total (gross income forAR} 2718.84 400031.48 402750.32 Totalrecelpts 402750.32 A3 Payments l.T & Computing Donations and Giants Bank & Payment Processing Fees 412.78 755.69 243.52 Sub total 1411.99 Totalpayments hletof recelpts1pa￿nents 400031.48 4oia38.33 A5 Tianslers between funds A6Cashfunds lastyearend 1618 2023 3641 Cash funds thls year end Independent Examiner'sl Auditorfs Re On accounts for the 1 $1 August 2025 period ended ort to the Trustees of Sidefxhub.UK Charlty no 1203385 Set out on pages 1 to5 I report to the trustees on my examination of the accounts of the above charity (Yhe Trust.) for the period ended 0110812025. Responsibilities and As the charity trustees of the Trust, you are responsible for the preparation basis of report of the accounts in accordance with the requirements of the Charities Act 2011 ('the Ad"). I report in respect of my examination of the Trust's accounts carried out under section 145 of Ihe 2011 Act and in cafrying out my examination, I have followed the applicable Directions given by the Charity Commission under sedion 14515)(b) of the Act. I have compleled my examinalion. I confirm that no material matters have come lo my attention in connection with the examination which gives me cause to believe that in. any material respect.. accounting records were not kept in accordance with section 130 of the Act or the accounts do not accord with the accounting records Independent examiner's statement I have no COn￿mS and have come across no other matters in connection with the examination to which altention should be drawn in order to enable a proper understanding of the accounts lo be reached. Slgned: Date: 31 May 2026 Name: Max Retallack Relevant professional qualification(s) or body {if any>: FCCA Addross: Nelson House, 2 Hamilton Terrace, Leamington Spa, Watwickshire CV32 4LY 7. Trustee Responsibilities Statement lTht l TUSi¢e8 (whi) &181) all as l)irL'Llors l()r Ll)mpany Inw purw)8c8) are responsible for prcpaTing thi% and ihL IIiiiiTli illl 4lnlLinenls in UL¢iTrrdanLe with applicable law and Llnilcd kingdi)iiI ALLiiunliii¥ %lwidiwdq {Tr 11121. .1 hcy mu¥l'. l. ScleLI and appl), suiLqble QLLiiunling p()IiLic8 Ll)n8181Lnily. 2. Obscr4C IhL mclh(xls wid PriTiciple5 in thL ('huriliLS SUKP. l. M8kL re&son8ble Jnd prudcnl judginL Til.% and e81imalcs. 4. P￿.pare the tin3n¢ial silltLmLnls un ll goinb7.L(ift¢crn h&8is unle88 inappropriale. 5. Mainthin adcqualc a¢iounlin8 reL'OTds and implcmenl effeciive internal controls. App ved by ihe Board of Trujttts on 28 May 2026 athd Jigned on its beh*ir ixon. Chair ary Shield& Tra8urer be published by the end of 2026, with progress being made for the start of clini¢al trials Stakeholder Collaboration: Continued data-sharing frameworks with University of Milan and UK research partners for parallel studies are still being developed. Public Awareness: Extremely positive and extensive multiple media successes were made in this accounting period. TV, Radio and Press coverage reached many millions. The charity is now regularly receiving enquiries from media outlets for itTrformed comment.. Regulatory Engagement: We Continu¢ to engage with the MHRA and other int¢rnattonal drug regulatory agencies Challenges: We continue to struggle to secure repeat funding from a donor base that Is largely fmancially compmmised. At the same time. we must be mindful of the need for future projects, whilst managing reserves prudently and responsibly. 5. Financial Review Funds carried forward: Total Incomlng resources: Total re50urtes expended: Net movement in funds: Cash funds carried forward: £3,641 £402,750.32 £1411.99 £406,391.32 £406,391.32 Reserves Policy: Trustees aim to hold unrestricted reserves equivalent to approximately 12 months of running costs (c. £1,500). As at l August 2024, free reserves stood at £2,924.85, as trustccs await decisions regarding ￿tllre research donations. Prill¢ipal Funding Sourees: Individual donations, raised on the understanding that donors will not be placed in financial hardship by their contributions. 6. Plalls for Future Periods l. Diversify Funding BYd8e.. 'larget corporate donors, private philanthropic foundations and governm¢nt grant programmes. 2. Patient Database Project: Secure cor¢ funding to develop a comprehensive patient registry to idenlify symptom-proftle patterns and potential biomarkeTS. 3. Digital Outreach: Launch a YouTube channel to serve as an accessible inforniation hub for PF S and PSSD communities. 4. Political Engagement: Lobby key MPS and forn] a cross-party group to influence men's and young people's health policy, enhancing submissions to regulators and scientific nomenclature bodies. 3. Objectives, Public Benefit and Activities Charilable Objects. To promote scientific research into the prevention. cure, management and alleviation of iatrogenic dtse&se-including, but not limited to, Post-Finasteride Syndiome-by providing funding on the condition that useful research r¢sults are disseminated for public benefit. Public Benefft: Th¢ trustees confjrni that they have had due regard to the Charity Commission's public benefit guidance in planning and d¢livering activities during the rewrting period. By fimding independent scientific researclL raising awareness among healthcare professionals and the wider public. and facilitating improved adverse- effect r¢porting, the charity has continued to.. Advan¢¢ understanding of PFSIPSSD pathophysiology. knefiting cu￿ent and ￿tUre patients through peer-reviewed publications and data-sharing networks. Improve pali¢nt outcomes by disseminating practical inforn]ation and resources, leading to earlier recognition and management of adverse effects by clinicians. Enhance regulatory safeguards by collaborating with the MHRA to refine adverse- ¢vent reporting workfiows, reducing the risk of under-reporting and safeguarding public health. Activities during 2 Augusl 2024- 1 August 2025: Fundraising: Raised £402,380, £400,000 of which is restricted by two anonymous donors, to be spent on research in progress and future potentially relevant projects. All donations are made in accordance with the Charity's docum¢nted donations policy. Funds are Predominantly received from patients and family members. Grant-making: Committ¢d approximately £750 to fund Professor Melcangi's "Milano Project" at the University of Milan, a seven-investigation initiative translating preclinical PFS findings toward human trials. Our trusted partner. Th¢ PFS Foundation, requested that we held off making a more substantial donation until after the accounting period to assist a joint fundraising initiative oCCu￿1ng laler in the year. Seientifie Engagement: We continued to search for and screen additional r¢s¢archers to investigate underlying mechanisms of PFS and Post-SSRI Sexual Dystunction (PSSD). A polential collaboralion with ihe University of Glasgow is still in ob¢yance. Awareness and Advoea¢y: Orchestrated TV, radio and press interviews to highlight the scale and severity of finasfrride sid¢-¢ffects. Engaged the MHRA to improve adverse-effect r¢porting accuracy and ttmeliness. Organised a specific outreach programme aim¢d at health professionals involved with those suffering from PFS and PSSD 4. Achievements and Performance Re5eareh Funding: Continued funding for two ongoing and five new clinical- translationa] studies within the Milano Project. Two peer-reviewed studies are due to Sid¢fxhub.UK Trustees, Annual Report for the period ending l August 2025 (Period: 2 August 2024 to l August 2025) l. Reference and Administrative Details Charity name: Sidefxhub.UK Registered ch¥drity number: 1203385 Registered office: 66 Leam T¢rrac¢. Leamington sp￿ CV311 BQ Trusttts who served during the period: l. Gary Shields (freasurer) 2. Katharine Hayden {S¢ientific oificer) 3. Bernard Morlet (Chair) 4. Rob¢rt Dixon (All truslee appointmenls arepaiienl- or bene]iciary-le4 or involvefamily members ofpalients, recruited by invitalion.) Board of Directors: l. Gary Shields 2. Mort¢n Skov 3. Robert Dixon 4. Bernard Morlet (Palient- orfamily-member-led, meeling at leasl weekly with daily commwiication as needed.) Key advisers: Independent Examiner: Max R¢tallack, TC Group Business Advisors & Accountants Bankers: The Co-op¢rative Bank Community Direct Plus Account (online) WISE Foreign Currency Account (online) 2. Structure, Governance and Management Sidefxhub.UK is constituted as a Charitable Incorporaied Organisation {CIO) under English law. Overall control is vested in the Board of Trustees, who set strategic direction and oversee governance. Day-to-day decision-making is delegated to a patient-led Board of Directors. which meets weekly (with continual and frequent daily liaison) to manage Ol￿tionS and put th¢ trustees, policies into practice. A fomial ri5k-register is mainlained and r¢viewed quarterly, covering financial stsbility. safeguardin& and regulatory complian¢¢.